Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Zomedica Appoints PCG Advisory Group for Investor Relations and Announces Option Grants


ANN ARBOR, Mich., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (TSX-V:ZOM) ("Zomedica"), a veterinary pharmaceutical and health care solutions company, today announced that it has retained PCG Advisory Group, a leading integrated communications firm, to serve as an advisor for investor relations and social media communications strategies.

“We are very pleased to announce that we have engaged PCG Advisory Group to communicate our story concurrent with our near term goal to list on a major U.S. exchange,” stated Gerald Solensky Jr., Chief Executive Officer of Zomedica. “The PCG team is known for their dedication to the U.S. micro and small cap market, their vast network of investors and digital/social media expertise. The selection of PCG Advisory Group reflects our desire to further support our goals by strategically presenting our corporate and investor message to a wide audience of U.S. investors via traditional investor relations and social and digital media initiatives. As we continue to add depth to our product pipeline as well as strategic collaborations, now is the time to ensure the Zomedica investment case is heard throughout the investment community. We believe that PCG’s broad approach and senior team is the right partner for raising awareness across the stakeholder spectrum.”

“We look forward to working together with the team at Zomedica to achieve their communications and stakeholder awareness goals,” said Jeff Ramson, Founder and Chief Executive Officer of PCG Advisory Group. “With a clear focus on developing a diversified portfolio of diagnostics, devices, innovative drugs, and drug-delivery technologies, Zomedica is well positioned to capitalize on the growth opportunity in the veterinary pharmaceutical and health care solutions market. We believe Zomedica’s investment case and outlook for growth, supported by its developing product pipeline while investigating strategies for domestic and global commercialization, will resonate well across PCG’s networks of investors, bloggers, journalists, and other key stakeholders. With positive growth potential coinciding with a U.S. investment community focus, we are pleased to embark on a targeted stakeholder marketing initiative.”

Zomedica has entered into an agreement with PCG Advisory Group (which is subject to approval of the TSX Venture Exchange (“TSX-V”), the consideration under which shall consist of a monthly fee payable by Zomedica in the amount of US$7,500, commencing August 14, 2017 for a period of twelve months ending on August 13, 2018. Zomedica may terminate the agreement at any time after February 14, 2018 upon the provision of 30 days written notice. PCG Advisory Group has also been granted stock options to acquire up to an aggregate of 75,000 Common Shares of Zomedica. Each of the stock options is exercisable for a one-year term expiring on August 14, 2019 at price of C$2.75 per Common Share. Such options vest quarterly over a period of one year and shall be subject to regulatory approval and the provisions of Zomedica's Stock Option Plan.

Zomedica also announces that, pursuant to its stock option plan, it has granted stock options to acquire up to an aggregate of 1,205,000 Common Shares, of which, 1,100,000 stock options were granted to certain officers of Zomedica. Each of the stock options is exercisable for a two-year term expiring on August 14, 2019 and exercisable until that time at a price of C$2.75 per Common Share. On August 11, 2017, the last day that the Common Shares traded prior to the granting of the stock options, the closing price of the Common Shares on the TSX Venture Exchange was C$2.40 per share. The foregoing stock options all vested immediately upon the date of grant. All of the stock options announced herein (including those granted to PCG Advisory Group), and any Common Shares issued upon exercise of the stock options, are subject to standard hold period restrictions, including a four-month hold period under Canadian securities laws expiring on December 15, 2017.

About Zomedica
With U.S. operations based in Ann Arbor, Michigan, Zomedica is a veterinary pharmaceutical and health care solutions company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. Zomedica is developing a diversified portfolio to include diagnostics, devices, innovative drugs, and drug-delivery technologies. With a team comprised of clinical veterinary professionals, it is Zomedica’s mission to give veterinarians the opportunity to lower costs, increase productivity, and grow revenue while better serving the animals in their care. For more information, visit

Follow Zomedica

Reader Advisory
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the release.

Except for statements of historical fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.

Forward-looking information is based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether our strategies and business plans will yield the expected benefits; availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to future clinical trials, regulatory approvals, safety and efficacy of our products, the use of our product, intellectual property protection and the other risk factors disclosed under our profile on SEDAR at Readers are cautioned that this list of risk factors should not be construed as exhaustive.

The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.

Investor Relations Contact Shameze Rampertab, CPA, CA +1 647.283.3630 PCG Advisory Group Kirin Smith, COO +1 646.863.6519 Media Contact Andrea Eberle +1 734.369.2555

Primary Logo